A 65-year-old taking nilotinib for chronic myeloid leukaemia develops symptomatic peripheral arterial disease. What management principle is most

Question

A 65-year-old taking nilotinib for chronic myeloid leukaemia develops symptomatic peripheral arterial disease. What management principle is most appropriate?

Accepted Answer

Urgently review the tyrosine-kinase inhibitor with haematology and intensify cardiovascular risk management

Answer

Stop all CML treatment permanently before completing arranging an alternative

Answer

Treat the leg symptoms and maintain the current cardiovascular plan after successful revascularisation

Answer

Continue nilotinib unchanged because arterial occlusion is unrelated to BCR-ABL inhibitors

Answer

Add long-term triple antithrombotic therapy before completing assessing bleeding risk or the anticancer regimen

Nilotinib Vascular Toxicity — RACP Adult Medicine MCQ

A 65-year-old taking nilotinib for chronic myeloid leukaemia develops symptomatic peripheral arterial disease. What management principle is most appropriate?